Phase i/II randomized, prospective, double-blinded, sham-controlled cross-over study of intravitreal autologous bone marrow CD34+ stem cell therapy for retinal vein occlusion
Ended Cooperative Agreement Awarded Last action
- Award ID
- UG1EY028517
- Recipient
-
The Emmes Company, LLC UEI NBQCBJ6FXBU4
- Awarding agency
-
National Eye Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $2,820,947
Award facts
- Assistance listing
- 93.867 Vision Research
- Completion date
- Originally
- Funding
-
- $2,537,586.00 Federal
- $283,361.00 Non-federal
- Place of performance
- Maryland, USA
Award details come from USAspending.gov.
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $315,485 | $0 | |
| Amendment | $315,485 | $0 | |
| Amendment | $283,361 | $0 | |
| Amendment | $283,361 | $283,361 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $431,909 | $0 | |
| Amendment | $433,262 | $0 | |
| Amendment | $0 | $0 | |
| Original award | $474,723 | $0 |
Show all 25
Quick answers
Who received award UG1EY028517?
UG1EY028517 was awarded to The Emmes Company, LLC by National Eye Institute (National Institutes of Health) on June 15, 2018.
How much is award UG1EY028517 worth?
$2,820,947 has been obligated on UG1EY028517: $2,537,586 in federal funding and $283,361 in non-federal funding.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award